COST ACTION CA21111 - OneHealthdrugs (One Health drugs against parasitic vector borne diseases in Europe and beyond)
The recent COVID19 pandemic infection has undisclosed long-standing issues in the translation of drugs from animals to humans or vice-versa. Nearly 75% of emerging human infections worldwide originated from animals; existing drugs for human and animal (H&A) vector-borne diseases (VBD) are scarce, with limited efficacy, toxicity, and finite resources. Emerging environmental problems in pharmaceutical use/manufacturing increase attention in the field. The two drug pipelines are developed independently. Hence, cooperation is needed among different expertise to define how it is possible to develop new drugs in a more sustainable approach.
OneHealthdrugs aims at coordinating the discovery of drugs halting H&A VBD keeping with the principles of optimal profile for both organisms, increasing the quality and delivery technologies. The COST Action is the ideal platform aiming at the integration and generation of synergies among drug R&D experts from the chemical/biological/human/veterinary and earth science within academies, SMEs, industries, governments. The platform encompasses pre-clinical drug discovery, animal studies, and drug delivery. Strategies such as bioinformatics, PROTAC, nanotechnology will be enhanced.
OneHealthdrugs will impact in Europe and in disease-endemic countries. The Action will provide a compounds database and a white chart about the discovery of new drugs for H&A infections. Expected benefits include the transfer of academia-industry and Northern-Southern world knowledge. Conferences, training schools for advanced technologies, and STSMs are planned. Novel communication technologies to disseminate the Action results to a broad audience including scientists, stakeholders, and citizens are planned. Young researchers will be trained on advanced techniques.
Web page: https://onehealthdrugs.com/Funding details:
- People (19)
- Projects (6)
- Institutions (19)
- Data files (0+1)
- Publications (2)
- Presentations (0+1)
- Events (1+1)
- Documents (3+2)
Institutions: University of Maltahttps://orcid.org/0000-0002-6999-3667
Expert in the chemical sciences with specialisation in chemical synthesis and molecular logic-based computation.
Projects: WG2 - Integration of early phase studies and low environmental impact actions, WG6 - Promote the transfer of knowledge, WG5 - Promote dissemination, WG1 - Compound libraries coordination and integration of compound design
Institutions: Università degli Studi di Sienahttps://orcid.org/0000-0003-2574-3911
Expertise: structural biology, Cancer research, parassite research, drug development, antibiotic resistance, drug resistance, antibacterial drugs, neurodegenerative diseases, metalloproteins, protein-protein interactions, protein production
Projects: de.NBI-SysBio, Kinetics on the move - Workshop 2016, Example use cases, SBEpo - Systems Biology of Erythropoietin, FAIRDOM & LiSyM & de.NBI Data Structuring Training, FAIRDOM, EnzymeML, GMDS Project Group "FAIRe Dateninfrastrukturen für die Biomedizinische Informatik", FAIRDOM Community Workers, MIX-UP, COVID-19 Disease Map, ERNEST Mapping Group Pilot Study, NMTrypI - New Medicines for Trypanosomatidic Infections, Standardization of enzyme-catalyzed reaction measurement, Standardization of enzyme-catalyzed reaction modelling, ModeleXchange initiative, CoVIDD - Coronavirus interactions in drug discovery - optimization and implementation, Mass spectrometry proteomics for biomarker discovery, Thymidylate synthase dimer dissociation, WG1 - Compound libraries coordination and integration of compound design, WG2 - Integration of early phase studies and low environmental impact actions, WG3 - Coordination of in vitro-to-in vivo translation of OneHealth leads and candidates, WG4 - Integration of R&D process-environmental studies and translation in informed whitepaper, WG5 - Promote dissemination, WG6 - Promote the transfer of knowledge, SABIO-VIS, SDBV/HITShttps://orcid.org/0000-0002-9077-5664
Authors: A. Papa, S. Pasquini, F. Galvani, M. Cammarota, C. Contri, G. Carullo, S. Gemma, A. Ramunno, S. Lamponi, B. Gorelli, S. Saponara, K. Varani, M. Mor, G. Campiani, F. Boscia, F. Vincenzi, A. Lodola, S. Butini
Date Published: 15th Jan 2023
Publication Type: Journal
PubMed ID: 36462439
Citation: Eur J Med Chem. 2023 Jan 15;246:114952. doi: 10.1016/j.ejmech.2022.114952. Epub 2022 Nov 25.
Authors: Alex D. Johnson, Joseph A. Buhagiar, David C. Magri
Date Published: 15th Dec 2021
Publication Type: Journal
Citation: RSC Med. Chem. 12(12):2060-2064
The workshop “Novel leads and drugs and their mechanism of action in the field of vector borne parasitic disease” is jointly organized by WG1 “Compound libraries coordination and integration of compound design” and WG2 “Integration of early phase studies and low environmental impact actions” of the COST Action CA21111 OneHealthDrugs. The focus of the workshop is to bring together experts to report and discuss common definitions of novel leads and drugs and their mechanisms of action in view also ...
Start Date: 15th May 2023 (15th May 2023 (Europe/Berlin))
End Date: 15th May 2023 (15th May 2023 (Europe/Berlin))
Event Website: Not specified
Country: Not specified
This survey is organized by WG1 (Compound libraries coordination and integration of compound design) of COST Action CA21111 "OneHealthDrugs" and collects information from COST Action members about the handling of chemical compound information and the usage of compound databases/repositories. The results will help to coordinate and integrate compound data from different resources for searching and screening purposes by the COST Action participants.